

Photo Release -- NASDAQ Welcomes Intersect ENT (NASDAQ: XENT) to The NASDAQ Stock Market

NEW YORK, July 24, 2014 (GLOBE NEWSWIRE) -- The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) announced that trading of Intersect ENT (Nasdaq:XENT), a commercial drug-device company, commenced on The NASDAQ Stock Market on July 24, 2014.

A photo accompanying this release is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=26697>.

Intersect ENT, Inc. is a commercial drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions. Intersect ENT's drug-eluting bioabsorbable implant technology enables targeted and sustained release of therapeutic agents. Intersect ENT's initial products, PROPEL and PROPEL mini, are the first and only drug-eluting implants approved for use in patients with chronic sinusitis. Intersect ENT is developing new, less invasive and more cost-effective drug-eluting bioabsorbable treatment options for the management of chronic sinusitis in the physician office setting to provide benefits for patients, physicians and payors.

"We congratulate Intersect ENT on its successful initial public offering and we are pleased to welcome them to The NASDAQ Stock Market's family of listed companies," said Nelson Griggs, Senior Vice President, Corporate Client Group, NASDAQ OMX.

By listing with NASDAQ, Intersect ENT joins some of the world's largest and most revolutionary healthcare companies. NASDAQ has been the exchange of choice to 94 percent of healthcare companies that have listed on the U.S. markets year-to-date in 2014.

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding NASDAQ-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

About The NASDAQ OMX Group

NASDAQ OMX (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,400 listed companies with a market value of over \$8.5 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaqomx.com.

The photo is also available via AP PhotoExpress.

NDAQG

CONTACT: MEDIA RELATIONS CONTACT:

Will Briganti

(646) 441-5012

william.briganti@nasdaqomx.com



Intersect ENT (Nasdaq:XENT), a commercial drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions, opened for trading on The NASDAQ Stock Market on July 24, 2014.

Christine Barna

(646) 441-5310

Christine.Barna@nasdaqomx.com



Source: The NASDAQ OMX Group, Inc.

News Provided by Acquire Media